Video

View G. Steven Burrill's Presentation from BioConference Live
November 17, 2009.

View video 

Podcast

Jerry Flanagan, healthcare policy director for ConsumerWatchdog, discusses his group’s lawsuit against Anthem Blue Cross of California over its rate hikes, what they mean for healthcare reform, and why the proposed healthcare legislation wouldn’t have prevented Anthem from instituting the rate increases in the first place.
Hear the podcast 

G. Steven Burrill

Welcome from the CEO

Flash required to view this video. Download the latest version here

 G. Steven Burrill 

News

Biotech posts gain in February as broader markets strengthen March 03, 2010 | Press Release

Biotech holds steady in January as broader markets head south February 01, 2010 | Press Release

Biotech Closes the Year on an Upswing January 04, 2010 | Press Release

  See all News
 
Sign up for a free subscription to The Burrill Weekly Brief 
Sign up to receive email notifications about our upcoming events and news.


October 2009: Free Preview Issue » Get Access Now

This January, The Burrill Report will launch as your monthly window into the business of biotechnology. We invite you to download a sample issue today

May 2009: The Stem Cell Issue » Get Access Now


Topics covered »
Stem Cells

Regeneration of its Own
With the federal government readying to take a leadership role in funding stem cell research, the voter-created California Institute for Regenerative Medicine will need to rethink its role.

Running Over Roadblocks
France’s stem cell research policies are neither Europe’s easiest or toughest but the country has managed to make progress in regenerative technologies, despite restrictions. The current bioethics law is up for review, suggesting change may be ahead.

A New Tune
After years of watching the development of the emerging stem cell field from a distance, Big Pharma is starting to embrace the technology. One near-term payoff may come in new tools for drug development.

Cell Mates
CEO John Walker says iZumi’s collaboration with Kyoto University on pluripotent cells could ultimately lead to breakthroughs in drug development and therapeutics.

Gimme Shelter
A lab building boom is underway in California thanks to money raised by the state’s stem cell agency. The race is on as 12 institutions must complete building their state-of-the art research facilities by mid 2010.

Economy

Fishing for Biotech
Country and state economic development departments are going to great lengths to lure industry players.

Law

Personalized Medicine's Achille's Heel
Some of the very things that are needed to make tailor-made therapies possible—including biomarkers and diagnostic screening tests—could be difficult to patent, threatening the field’s development.

Financing

In the Red
Although posting positive numbers in March, with the Burrill Biotech Select Index up 3.7 percent, biotech along with the rest of the general markets, took quite a pounding in the first quarter of 2009.
  • US Biotech Financings
  • Partnering Robust
Public Biotech Companies Ranked by Market Cap
Q1 2009 global industry analysis

By The Numbers
Stem Cell Financings

Stem Cell Directory
 Over 200 Stem Cell companies profiled from the following countries:
  • Australia
  • Asia
  • Europe
  • Canada
  • United States

The Burrill Report provides information, intelligence, and insight on the life sciences industry. This unique resource consists of a quarterly digital magazine focused on revealing the people, technologies, financings, and strategies behind the life sciences industry’s next success stories. The publication differentiates itself from other titles by chronicling how the life sciences industry operates as a business.

Written for executive-level professionals, The Burrill Report provides detailed market intelligence you need to obtain an accurate overview of the latest global developments and trends. Your subscription also entitles you to monthly updates to global industry statistics, a series of special reports, and the Burrill Report Weekly Brief.

The Burrill Report serves as an ideal companion to Burrill & Company’s annual review of the industry. Every year, for the past 23 years, we have analyzed what has transpired during the year that has just ended and looked ahead to what is likely to come in the upcoming 12 months. To bridge the gap between these seminal reports, The Burrill Report serves as the industry’s report card and provides actionable analysis and data on biotech’s performance on the capital markets, the money being raised, the partnerships and acquisitions , and the scientific research and regulatory and political events that are shaping our industry.

The Burrill Report also has a human face. In addition to detailed market intelligence, which provides an accurate overview of the latest global developments and trends in the industry, we feature interviews with biotech CEOs, scientists, venture capitalists, and policy makers on topics of interest to the life sciences community as well as case studies and profiles on companies and organizations.

 

Your 2009 Subscription includes the following Issues:

May 2009: The Stem Cell Issue
Including Q1 2009 global industry analysis, this 120-page “By the Numbers” feature is published quarterly and is biotech’s global report card.
  • Special Feature: Directory Of Over 200 Stem Cell Companies
August 2009: Q2 2009 Global Industry Analysis

“By the Numbers” biotech’s global report card for second quarter of 2009

BioGreenTech Focus–tracking the investments and activities in agbiotech, biofuels and biocleantech

  • Articles on the what could be the greatest economic opportunity of the 21st Century


November 2009:Q3 2009 Global Industry Analysis
 “By the Numbers” biotech’s global report card for the third quarter of 2009

  • Feature on personalized medicine, which has the power to transform healthcare within the foreseeable future, and is already having a disruptive impact on the U.S. healthcare system. Also included is a 300-page Directory of companies/organizations.


February 2010*: Q4 2009 Global Industry Analysis
“By the Numbers” biotech’s global report card for the third quarter of 2009
The year ahead issue

  • Book of lists: Top Biotech Companies, Top Deals, etc.

Regular Departments

By the Numbers
A global round-up of the capital markets and stock market performance of over 300 biotechnology companies.

Indices
Indices charting the biotech industry stock market performance, on a monthly and quarterly basis. These include:
  • Burrill Biotech Select Index
  • Burrill LARGE-CAP Biotech Index
  • Burrill MID-CAP Biotech Index
  • Burrill SMALL-CAP Biotech Index
  • Burrill Life Sciences Index
  • Burrill Agbio Index
  • Burrill Genomics Index
  • Burrill BioGreentech Index
  • Burrill Diagnostics Index
  • Burrill Nutraceuticals Index
  • Burrill Life Science Composite Index
  • Burrill Personalized Medicine Index
  • Burrill Stem Cell Index
  • Burrill Canadian Biotech Index
  • Burriill India Life Sciences Index

Partnering and M&A
Canada, China, Europe, India

  


Subscription

The Burrill Report 2009–2010: $499.00